TuHURA Biosciences (HURA) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed TuHURA Biosciences (HURA) over the past year, gaining 36.2% versus a loss of 24.0%. Over five years, VTVT leads with a -47.0% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($124.9 million vs $123.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | VTVT |
|---|---|---|
| Share price | $1.96 | $31.18 |
| Market cap | $124.90M | $123.28M |
| 1-day change | +1.55% | +3.66% |
| YTD return | +158.92% | -22.03% |
| 1-year return | -24.03% | +36.22% |
| 5-year return | -99.87% | -46.97% |
| EPS (TTM) | $-0.54 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $44.00 |
| 52-week low | $0.41 | $19.50 |
| Distance from 52-week high | -42.86% | -29.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +310.20% | +75.47% |
| Average volume | 244.46K | 67.47K |
| Shares outstanding | 63.73M | 3.95M |
| Employees | 22 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed HURA by 60.2 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
HURA vs VTVT FAQ
Which is bigger, TuHURA Biosciences or vTv Therapeutics?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $124.90M compared with $123.28M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, HURA or VTVT?
VTVT returned +36.22% over the past 12 months, compared with -24.03% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.